Chemistfrog
Long only, growth, momentum, contrarian

Oxygen Biotherapeutics Makes Recent Progress In An Under-Met Indication

Oxygen Biotherapeutics (OXBT) reported last Tuesday, June 18th, that it had completed preclinical trials on animals evaluating its lead drug candidate, Oxycyte, for potential effects on the body's immune system. Oxycyte® is a perfluorocarbon-based intravenous oxygen carrier with multiple potential uses. Lead trials are focusing on the ability of the treatment to rapidly deliver oxygen to the patient's brain after a traumatic brain injury (TBI) to reduce acute damage and long-term complications. While news came out on the 18th, the company's stock action has been gradually responding with increasing liquidity and share price, although the overall markets have put a drag on share price this week. With a split-adjusted 52-week range of $2.53-$34.40, I believe Wednesday's closing share price...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details